Compare Expedia Group Inc (EXPE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs TG Therapeutics Inc — how do they compare? Expedia Group Inc trades at $274 (market cap $32.42B), while TG Therapeutics Inc trades at $55.11 (market cap $8.16B). The key difference: Expedia Group Inc is far larger — about 4× TG Therapeutics Inc's market cap, and Expedia Group Inc pays a 0.71% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 47 Days and TG Therapeutics Inc for 16 Days on average.
| EXPE | TGTX | |
|---|---|---|
Market Cap | $32.42B | $8.16B |
Volume | 1,940,671 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $339.13 | $59.06 |
52-Week Low | $188.51 | $26.94 |
Typical Hold Time | 47 Days | 16 Days |
Enterprise Value | $30.98B | $8.37B |
Dividend Yield | 0.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $271.44, up 4.86% today, showing strong momentum after recent earnings beats. The stock exhibits a bullish technical signal, trading near resistance at $275, with solid fundamentals including a P/E of 16.99 and robust revenue growth to $14.73B in 2025. Recent news highlights competitive threats from AI agents but also underscores Expedia's strategic partnerships and B2B booking strength.
The outlook remains positive with a consensus price target of $335.06, implying 23% upside, supported by earnings momentum and market share gains. Key risks include AI disruption in travel booking and competitive pressures. Institutional sentiment is mixed but leans bullish, with growth in operating cash flow to $3.9B in 2025 providing a solid foundation.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
